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1. Introduction
Adhesions are defined as abnormal attachments between tissues and organs [1]. Intra-ab‐
dominal adhesions may be classified as congenital or acquired [2]. Congenital adhesions are
a consequence of embryological anomaly in the development of the peritoneal cavity. Ac‐
quired adhesions result from the inflammatory response of the peritoneum that arises after
intra-abdominal inflammatory processes (e.g. acute appendicitis, pelvic inflammatory dis‐
ease, exposure to intestinal contents and previous use of intrauterine contraceptive devices),
radiation and surgical trauma [3]. It has been reported that the majority of acquired adhe‐
sions (about 90%) are post-surgical [2].
Factors associated with the formation of post-surgical adhesions include tissue trauma, in‐
fection, ischaemia,reaction to foreign bodies (sutures, powder from gloves, gauze particles
etc.), haemorrhage, tissue overheating or desiccation and exposure to irrigation fluids [4].
The incidence of intra-abdominal adhesions ranges from 67% to 93% after general surgical
abdominal operations and from 60% to 90% after gynecological procedures. Not unexpect‐
edly, adhesion formation is considered one of the most common post-operative complica‐
tions [2,5]. Post-surgically, many adhesions may be asymptomatic or can lead to a broad
spectrum of clinical problems, including intestinal obstruction, chronic pelvic or abdominal
pain and female infertility, requiring re-admission and often additional surgery, while at the
same time they can complicate future surgical procedures [6]. Adhesion-related re-opera‐
tions are a common consequence of gynecological procedures and adhesiolysis is followed
by a high incidence of adhesion reformation and de-novo adhesion formation [7].
The major strategies for adhesion prevention in gynecological surgery aim at the optimiza‐
tion of surgical technique and use of adhesion-prevention agents. Laparoscopic surgery in
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gynecology represents the most innovative surgical approach, compared with laparotomy
since it has been shown from a large number of clinical, but also experimental studies, that
is associated with less development of de novo adhesions. Without any doubt, the most im‐
portant factor is the operating surgeon, whose attention to proper surgical technique will
serve as a mainstay for adhesion formation.
2. Mechanism of adhesion development
The mechanism of adhesion formation represents a variation of the physiological healing
process [8]. The process of peritoneal healing differs from that of other tissues. Peritoneal
defects heal by a process of metaplasia from the underlying mesenchyme, partly from mi‐
gration of epithelial cells from the free peritoneal fluid and minimally through proliferation
of epithelial cells from the defect’s edges. Consequently, peritoneal wounds need the same
time to heal regardless of their size, in contrast with other tissues, such as the skin, where
large injuries take longer to heal than do small injuries [9]. There is no difference between
peritoneal healing and adhesion formation for the first 3 days after peritoneal injury. Injuries
to the peritoneum cause a disruption of stromal mast cells, resulting in the release of hista‐
mine and vasoactive cinins. Also as a response to trauma, various cytokines, such as inter‐
leukin (IL)-1, IL-6 and tumor necrosis factor-a (TNF-a) are locally released. The cytokines
attract and activate macrophages to secrete vasodilating substances, which in turn, cause an
increase in capillary permeability, leading to the formation of fibrous exudate [10]. Platelets
are an important component of the inflammatory exudate and have the ability to adhere it to
the traumatized surfaces. The platelet degranulation releases adrenaline, transforming
growth factor b and serotonin and contribute to the production of prostaglandins and leuko‐
trienes. The chemokines direct the migration of cells to the injury site, while platelets con‐
tribute to the initial fibrin clot and to the initiation of the coagulation process [11]. The
activation of the coagulation cascade leads to the transformation of the inactive prothrombin
into thrombin that triggers the conversion of fibrinogen into monomers of fibrin, which in‐
teract and polymerize. The initially soluble polymer becomes insoluble by coagulation fac‐
tors such as factor XIIIa [12]. The exudate coagulates within 3 h and forms a fibrinous
material that plugs the defective area and generates attachments between adjacent tissue
surfaces. The presence of blood and post-operative bleeding increases the fibrin deposition.
Most of the fibrin depositions will disperse by fibrinolysis. The fibrinous mass that will re‐
main, results in the organization and formation of adhesions [8]. Polymorphonuclear cells,
macrophages, fibroblasts and mesothelial cells migrate and proliferate into the fibrinous
exudate. Macrophages increase in number, change function and secrete a variety of substan‐
ces that recruit mesothelial cells onto the injured surfaces. Mesothelial cells form islands,
proliferate and cover the injured area. All these cells release a variety of substances such as
plasminogen activator, plasminogen activator inhibitor, arachidonic acid metabolites,reac‐
tive oxygen species, cytokines, IL-1, IL-6, tumor necrosis factor-a, prostaglandin E2, collage‐
nase, elastase and the transforming growth factors leukotriene B4 a and b(TGFa and TGFb).
These factors modulate the process of peritoneal healing and adhesion formation [12-14].
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The deposition is the key step for the healing process and the balance between deposition
and degradation will determine normal peritoneal healing or adhesion formation. The fibrin
absorption is controlled by fibrinolysis. The inactive plasminogen is converted to plasmin
through tissue plasminogen activator (tPA) and urokinase type plasminogen activator
(uPA). The tPA is present in both mesothelium and submesothelial blood vessels of serosal
and peritoneal membranes[12,15]. The fibrinolytic activity normally begins three days after
peritoneal injury and increases to a maximum by day 8. Therefore, those adhesions that will
be formed are in place by day 8, when mesothelial regeneration has been completed [8].
Normal peritoneum has a high fibrolytic activity in order to prevent adhesion formation be‐
tween different tissue surfaces. During the inflammatory process, IL-1 and IL-6 stimulate
epithelial and inflammatory cells to release plasminogen activator inhibitor 1 and 2 (PAI-1
and PAI-2), which inhibit fibrinolytic activity [16]. Patients with extensive adhesions have
been found to have an overexpression of PAI-1 in the peritoneum [17]. Also, the deficient
blood supply, the reduced tissue oxygenation and the release of reactive oxygen species that
frequently co-exist with surgical trauma, decrease the peritoneal fibrinolytic activity [9,18].
3. Adhesion prevention
In order to prevent the development and reformation of post-operative intra-abdominal adhe‐
sions a variety of surgical techniques and adjuvants have been proposed. Agents, that in theory
can modify the mechanism of adhesion formation, have been evaluated in experimental trials
and many of them have been advocated for use during surgery in humans. Surgical techniques
are focused on the limitation of surgical trauma, prevention of ischaemia and exposure of peri‐
toneal cavity to foreign materials (Table 1). Improvement of surgical techniques can potentially
reduce adhesion formation but cannot eliminate it. Anti-adhesive agents can be classified as
pharmacological agents, systemic or intra-peritoneal, and intra-peritoneal barriers (solid or
liquid). Pharmacological agents (Table 2) target the modification of inflammatory reaction
(limitation of fibrin deposition), amplification of fibrin absorption and suppression of fibro‐
blast activity. Barriers (Table 3) are used in order to prevent traumatized peritoneal surface ap‐
position during the healing process so as to prevent tissue adherence [17,19].
Achieving excellent haemostasis and avoiding
local ischaemia
Avoiding foreign bodies (talc, starch)
Avoiding peritoneum suturing or use of fine
non-reactive suture
Minimizing surgical trauma
Minimizing tissue handling
Reducing drying or overheating of tissues
Reducing infection risk
Removing intra-peritoneal blood deposits
Table 1. Surgical techniques for prevention of adhesion formation
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Fibrinolytic agents
Anticoagulants
Anti-inflammatory
agents
Antibiotics
Other agents
Fibrinolysin
Papain
Streptokinase, streptodornase
Urokinase
Hyaluronidase
Chymotrypsin, trypsin, pepsin
Elastase
Recombinant tissue plasminogen activator
Citrates
Oxalates
Heparin
Corticosteroids
Antihistamines
Non-steroidal anti-inflammatory drugs
Tetracycline
Cephalosporin
Progesterone
Oestrogens
Gonadotrophin-releasing hormone agonists
Antiproliferative agents
Aromate inhibitors
Statins
Melatonin
Table 2. Pharmacological anti-adhesive agents
4. Laparoscopy and adhesions
The development of operative laparoscopy in gynaecology was associated with the expecta‐
tion of reduced adhesion formation. Therefore, a large number of experimental and human
clinical trials has been performed, which have shown that, compared with laparotomy, lapa‐
roscopic surgery is associated with less development of adhesions [17,20,21]. Reduction of
adhesion formation is facilitated by minimal tissue handling and trauma, avoidance of expo‐
sure to foreign bodies (powder from gloves, gauze particles, e.t.c.) and prevention of air pol‐
lution in the peritoneal cavity that leads to the reduction of tissue drying.
Pneumoperitoneum via increased intra-abdominal pressure has a tamponade effect that fa‐
cilitates haemostasis, limits the use of diathermy and formation of ischaemic areas. In addi‐
tion, laparoscopy is associated with a lower incidence of post-operative infection [21,22]. On
the other hand, it has been advocated that the beneficial effect of laparoscopy in adhesion
formation might be reduced by the use of pneumoperitoneum with CO2 [12]. CO2 pneumo‐
peritoneum is associated with increased intra-abdominal pressure that compresses the
splanchnic veins, reducing the blood flow by elevating vascular resistance. This stasis leads
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to a reduction in tissue oxygenation, anaerobic cell metabolism, acidosis and production of
reactive oxygen species. The clinical impact of reactive oxygen species remains unclear but
there is evidence that they are associated with increased adhesion formation [23]. Moreover
it has been recently proposed that a low intra-peritoneal pressure (IPP) (8 mmHg) may be
better than the standard IPP (12 mmHg) to minimize the adverse impact on the surgical per‐
itoneal environment during a CO2 pneumoperitoneum [24].
Solid barriers
(membranes, gel)
Endogenous tissue
Fluid barriers
Exogenous material
Omental grafts
Peritoneal grafts
Bladder strips
Fetal membranes
Various oils
Liquid paraffin
Amniotic fluid
Dextran
Crystalloid solutions
Icodextrin 4%
Polyglycan esters
Silicone
Vaseline
Gelatin
Metal foils
Elastic and silk foils
Expanded
polytetrafluoroethylene
Oxidized regenerated
cellulose
Hyaluronic acid
Carboxymethylcellulose
Polyethylene glycol
Polylactide
Fibrin, N,Ocarboxymethylchitosan
Table 3. Anti-adhesive barier methods.
5. Pharmacological agents
A wide variety of pharmacological agents (Table 2) have been used in attempts to prevent or
attenuate the formation of post-surgical adhesions, but none of them has been found to be
effective. The use of drugs for adhesion prevention has some obstacles that affect their effi‐
cacy. Ischaemia and inadequate blood supply are important factors in adhesion formation
and these also decrease systemic drug delivery inhibiting their effectiveness. Peritoneum
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has an extremely rapid absorption mechanism, that limits the half life and efficacy of many
intra-peritoneally administered agents. Anti-adhesion agents must not affect normal wound
healing, which has steps in common with adhesion formation (fibrinous exudate, fibrin dep‐
osition, fibroblast activity and proliferation) [19,25]. The clinical effectiveness of these agents
has been evaluated in a systematic review and meta-analysis that analysed data from rele‐
vant randomized controlled trials (RCT) published up to 2005 [26].
6. Non-steroidal anti-inflammatory drugs
Non-steroidal anti-inflammatory drugs (NSAID) affect adhesion formation by several mech‐
anisms. They act by modifying arachidonic acid metabolism and altering cyclooxygenase ac‐
tivities. This results in decreased vascular permeability, platelet aggregation, and
coagulation and enhanced macrophage function. A number of locally and systemically ad‐
ministered NSAID have been used in experimental trials.
No relevant clinical trials assessing the effectiveness of NSAID in adhesion prevention have
been published to date in patients undergoing gynaecological surgery. Their clinical efficacy
is questionable probably because of inadequate concentrations at the sites of surgical trauma
or by rapid absorption from the peritoneal membrane [3,19,27].
7. Corticosteroids and antihistamines
Corticosteroids alter the inflammatory response by reducing vascular permeability and de‐
creasing cytokine and chemotactic factor secretion. Antihistamines inhibit fibroblast prolif‐
eration and stabilize lysosomal membranes and histamine secretion. Corticosteroids have
been used alone or plus antihistamines by intra-peritoneal or systemic administration or
by flushing through Fallopian tubes post-operatively and were effective in many, but not
all, experimental models. In the limited data from RCT [28,29,30], no significant beneficial
effect was detected with the use of corticosteroids (systemic, intra-peritoneal or Fallopian
tube flushing) in the deterioration of adhesion score at second-look laparoscopy or on the
probability of clinical pregnancy. However, limited data suggest that the addition of post-
operative steroids to systemic intra-operative steroids might be associated with a favoura‐
ble  outcome  both  in  terms  of  adhesion  score  deterioration  (increase)  or  improvement
(reduction) [31]. On the other hand, adverse events such as suppression of the pituitary–
adrenal  axis,  immunosuppression and delayed wound healing have been reported with
the use of corticosteroids [19,32,33]. Regarding antihistamines, only one RCT has evaluat‐
ed the role of oral promethazine in the prevention of adhesion formation after pelvic sur‐
gery.  In  that  study,  no  significant  difference  was  detected  either  in  deterioration  or
improvement of adhesion score in patients who received promethazine as compared with
those who did not [31].
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8. Progesterone and oestrogens
Progesterone has been used for the prevention of post-operative adhesions. Administration
of progesterone resulted in less adhesion formation in animal models, but does not appear
to be effective in humans. Oestrogens have been associated with increased adhesion forma‐
tion in animal models. It was demonstrated that a hypo-oestrogenic state, produced by go‐
nadotrophin-releasing hormone agonists or aromatase inhibitors such as tamoxifen and
anastrazole, decrease development of post-operative adhesions in experimental models
[3,34,35]. This hypothesis, however, has never been tested in humans.
9. Anticoagulants – Fibrinolytics
Anticoagulants such as heparin can reduce adhesion formation by inhibition of the coagu‐
lation cascade and promotion of fibrinolysis [36].  The use of heparin for intra-peritoneal
irrigation in a dose that can reduce adhesion formation was associated with haemorrhage
and delayed wound healing, but low-dose heparin irrigation showed no benefit in adhe‐
sion reduction [3,19,37]. In the only available RCT, heparin delivery with oxidized regen‐
erated  cellulose  failed  to  demonstrate  a  superior  effect  compared  with  oxidized
regenerated cellulose alone [38].  Furthermore,  in  experimental  trials,  the  combination of
carboxymethylcellulose or 32% dextran 70 plus heparin failed to reduce adhesion forma‐
tion [38,39,40].
Fibrinolytic agents as streptokinase, elastase and tissue plasminogen activator produced by
recombinant DNA techniques (rtPA) can contribute in adhesion prevention directly by re‐
ducing the fibrinous mass and indirectly by stimulating plasminogen activator activity. Sys‐
temic administration of anticoagulants is impeded by lack of safety. The concentrations of
fibrinolytic agents required to prevent adhesion formation are too close to the anticoagulato‐
ry concentrations and increase the risk for post-operative haemorrhage and delayed wound
healing. Intra-peritoneal administration is ineffective due to rapid absorption by the perito‐
neal membrane [3,25,41]. The use of carboxymethylcellulose gel and oxidized regenerated
cellulose as a carrier to deliver rtPA intra-peritonealy was not associated with a reduction of
adhesion formation in animal models [42,43].
A recent study has investigated the impact of gonadotropin-releasing hormone analogue
(GnRH-a) on coagulation and fibrinolytic activities and its effectiveness in the prevention of
pelvic adhesion after myomectomy in thirty-two infertile women. Patients treated with
GnRH-a showed significant decrease in plasminogen activator inhibitorPAI, thrombin acti‐
vatable fibrinolysis inhibitor (TAFI), factors V, and VIII and increased protein C (PC), but no
significant change in plasminogen and α2-antiplasmin levels compared with control group,
suggesting a possible critical role of the GnRH-a therapy in preventing postoperative adhe‐
sion development [44].
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10. Antibiotics
Antibiotics are commonly used for prophylaxis against post-operative infections and hence
the inflammatory response that leads to adhesion formation. Peritoneal irrigation with anti‐
biotic solutions does not reduce adhesion formation, while it has been shown that in some
cases it may promote them [45].
11. Other pharmacological regimens
Many other agents, such as apoprotin, noxytioline, growth factor inhibitors and modulators,
phosphatidylcholine, thiazolidinediones, colchicine and calcium channel blockers, have
been utilized in experimental trials. The intra-peritoneal administration of noxytioline is the
only one of these interventions that has been tested in the context of a RCT and no signifi‐
cant difference was identified in terms of reduction of adhesions and clinical pregnancy
rates in patients who were administered intra-peritoneal noxytioline and the control group
[29]. There is no data from RCT to support the conclusion that any of the other agents is effi‐
cacious in preventing the development of post-operative adhesions [19,46,47].
12. Anti-adhesive barriers
The failure of pharmacological regimens to prevent adhesion formation has led to the reviv‐
al of the barrier technique. With the barrier technique, traumatized peritoneal surfaces are
kept separated, during mesothelial regeneration, thus precluding adherence of adjacent or‐
gans and tissues and reducing the development of adhesions. The separation can be ach‐
ieved by the use of solid (films or gels) or fluid barriers [19,25]. Anti-adhesive barriers are
currently the most useful adjuvant for prevention of post-operative adhesion formation. Nu‐
merous substances (Table 3) have been used as mechanical barriers to separate tissue surfa‐
ces. Most of these materials are of historical interest only and had no effect or even
aggravated adhesion formation [48,49]. An anti-adhesive agent should be effective, safe, eco‐
nomical and easy to use in both open and laparoscopic surgery [50]. The clinical effective‐
ness of several of these agents has been evaluated in two recent Cochrane reviews [26,51].
13. Solid barriers
Solid barriers are placed over one or between two traumatized surfaces providing a separa‐
tion that averts tissue apposition during the critical period of fibrin formation and mesothe‐
lial regeneration following surgical trauma. It should be noted though, that solid barriers
have some significant drawbacks. They are often ineffective in the presence of blood, have a
complex preparation and application, do not conform easily to the shape of pelvic organs,
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need suturing and are difficult to use via laparoscopic surgery. Their benefits are also limit‐
ed to the site of application and do not prevent the development of adhesions at sites of in‐
direct trauma. So the surgeon has to surmise where adhesions will be formed in order to
choose the placement sites and optimize barrier efficacy [52]. Not infrequently, this proves
to be a challenging task, since, for example, midline laparotomy initiates a generalized peri‐
toneal response that can lead to adhesion formation distant from surgical trauma [53].
14. Expanded polytetrafluoroethylene
Expanded polytetrafluoroethylene (Preclude, Gore-Tex Surgical Membrane; Johnson and
Johnson, Arlington, TX) is a non-absorbable, non-reactive, synthetic material that
inhibits cellular migration and tissue adherence. In the only available RCT, it has been
shown to be associated with fewer post-operative de-novo adhesions after myomectomy
when compared with no treatment [54]. Moreover, when compared with oxidized regener‐
ated cellulose, Preclude was found to be more effective in terms of adhesion reformation af‐
ter adhesiolysis [55]. However, in another RCT, no evidence of a beneficial effect of Preclude
was demonstrated in the de-novo formation of adhesions after laparoscopic myomectomy
when compared to oxidized regenerated cellulose [56]. Expanded polytetrafluoroethylene
has the disadvantages that it must be sutured in place, is difficult to use in laparoscopic sur‐
gery and, ideally, requires a subsequent surgical procedure for removal after the injury has
healed [57]. The use of Preclude in Europe is limited and it has been withdrawn from the
market in USA after the development of the absorbable barriers [25].
15. Oxidized regenerated cellulose
Oxidized regenerated cellulose (Interceed (TC7); Johnson and Johnson) is the first degrada‐
ble barrier that was used in clinical practice and represents a modification of its precursor
Surgicel, which has been used as a haemostatic agent for a long time. It is a mesh designed
to be placed over or between traumatized surfaces. About 8 h after the application in the
peritoneal cavity, it becomes a viscous gel and finally it is degraded to monosaccharides and
completely absorbed in about 2 weeks [3,22]. Oxidized regenerated cellulose use in laparo‐
scopic surgery is feasible [8]. In order to evaluate the efficacy of oxidized regenerated cellu‐
lose in the prevention of the development of post-surgical adhesions, many studies have
been carried out. A meta-analysis of 11 relevant RCT [51] has shown that the barrier is safe
and reduces significantly the incidence of de-novo adhesions, as well as the reformation of
adhesions as compared with no treatment in laparoscopy [58-62]. In laparotomy, the availa‐
ble RCT [63-68], when meta-analysed [51], demonstrated that a significant reduction in the
reformation (or mixture) of adhesions can be expected with the use of oxidized regenerated
cellulose as compared with the no treatment group. The product is site specific, thus the effi‐
cacy is limited to surgical situations where raw surfaces can be completely covered with the
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mesh and its benefit is limited to the site of barrier placement. The fundamental disadvant‐
age is that it becomes ineffective when the entire area is not completely haemostatic. The
presence of small amounts of blood in the peritoneal cavity or post-operative bleeding re‐
sults in blood permeating the mesh, fibrin deposition and, finally, adhesion formation
[8,69,70]. In addition, as reported previously, the combination of oxidized regenerated cellu‐
lose plus heparin resulted in a significant reduction of adhesion formation and reformation
in experimental models. This improvement in efficacy was not confirmed in clinical trials
[36,38,40]. Oxidized regenerated cellulose has been approved by the US Food and Drink Ad‐
ministration (FDA) for use in open surgery in the USA [69].
16. Hyaluronic acid
Hyaluronic acid (HA) is a linear polysaccharide with repeating disaccharide units that are
composed of sodium D-glucuronate and N-acetyl-D-glucosamine. It is a naturally occurring
component of many body tissues and fluids, where it provides mechanically protective and
physically supportive roles [69]. Various combinations of HA have been used for the pre‐
vention of adhesion formation. HA and carboxymethylcellulose (Seprafilm; Genzyme, Cam‐
bridge, Massachusetts, USA) is an absorbable membrane that dissolves and forms a
hydrophilic gel approximately 24 h after placement. It is a site-specific barrier and acts by
separating mechanically opposite tissue surfaces and lasts for 7 days. The HA is completely
cleared from the body within 4 weeks, but the absorption of carboxymethylcellulose is not
well known. It does not conform to the shape of pelvic organs as well as oxidized regenerat‐
ed cellulose and is usually used to prevent adhesions between the incision of anterior ab‐
dominal wall and bowel or omentum [71,72]. Its use in laparoscopic procedures is difficult.
In a blind prospective, randomized, multicentre study, the treatment of patients after myo‐
mectomy with Seprafilm significantly reduced the extent and area of post-operative uterine
adhesions [72]. Potential side effects include induced foreign body reaction, higher incidence
of pulmonary emboli and intra-peritoneal abscess formation, but these findings were not
statistically significant in the relevant trials [3,73]. High cost is another limitation because,
for an effective protection from intestinal obstruction, a mean of 4.5 sheets per patient is re‐
quired [25]. Seprafilm has been approved by the FDA for use in open surgery in the USA
[22]. Ferric hyaluronate 0.5% gel (Intergel; Gynecare, Sommerville, New Jersey, USA) is a
viscous gel that provides a broader coverage than previous site-specific agents. It was
shown to be easy to use in open and laparoscopic surgery. In relevant prospective random‐
ized trials, ferric hyaluronate was associated with a significant reduction of severity and ex‐
tent of post-operative adhesions and statistically significant improvement of the American
Fertility Society (AFS) and modified AFS scores at second-look laparoscopy [69,74,75]. It was
withdrawn from the market in 2003 because of problems with late onset post-operative pain
and rare reports of sclerosing peritonitis [25,76]. Low-viscosity 0.04% HA combined with
phosphate-buffered saline (Sepracoat; Genzyme) is a bioabsorbable macromolecular dilute
solution of HA that is cleared from the body in less than 5 days. The solution is applied in
the peritoneal cavity before any tissue manipulation in order to protect peritoneal surfaces
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from indirect trauma and finally before the end of the procedures [3,77,78]. In a blind, pro‐
spective, randomized, placebo-controlled multicentre study, where patients had undergone
open gynecological procedures, low-viscosity 0.04% HA resulted in a statistically significant
reduction of adhesions, as well as of the mean adhesion score, at second-look laparoscopy.
However, it was not effective in reducing post-operative adhesion formation at sites of di‐
rect surgical trauma [78]. It has been approved by the FDA for use in open surgery in the
USA [22]. HA cross-linked to HA (Hyalobarrier Gel; Baxter, Bracknell, UK) is a site-specific
highly viscous gel is considered as easy to use in laparoscopic and open surgery. In a pro‐
spective, randomized, controlled study where the rate of post-surgical adhesions after lapa‐
roscopic myomectomy was examined, cross-linked HA resulted in significantly more
adhesion-free patients [79]. Pregnancy rates at 6 and 12 months after laparoscopic myomec‐
tomy were significantly higher in patients treated with cross-linked HA [80]. In another
randomized trial, adhesion-free patients after laparoscopic myomectomy were greater in the
treatment group but the difference was not statistically significant. The incidence and severi‐
ty of adhesions was similar in both groups, but a significant reduction of uterine adhesions
was found in the treatment group [81]. When the data from the two aforementioned studies
were combined, a statistically significant reduction of adhesions during second-look laparo‐
scopy was detected in the group of patients treated with HA-cross-linked HA as compared
with the control group. Auto-cross-linked internal ester form of HA (ACP gel; Fidia Ad‐
vanced Biopolymers, AbanoTerme, Italy) has the biocompatibility of the original polymer
but higher viscosity and extended residence. It is a gel that has been shown to be efficacious
in reducing abdominal adhesions in experimental models [82,83]. Two prospective random‐
ized controlled trials have been published so far by the same group regarding the use of
ACP gel for the prevention of intrauterine adhesions after hysteroscopic surgery. In these
studies, ACP gel has been associated with a significant reduction in the incidence and the
severity of subsequent intrauterine adhesions [84,85]. A stratified analysis of these two stud‐
ies confirmed this finding by demonstrating a significant reduction in the proportion of pa‐
tients with adhesions at second-look hysteroscopy. Cross-linked thiol-modified HA with 4%
polyethyleneglycoldiacrylate (Carbylan-S and Carbylan-SX; CarbylanBioSurgery, Palo Alto,
CA, USA) is a bioabsorbable solution of HA. Carbylan-S is a hydrogel and Carbylan-SX has
two formats, a sprayable gel and a hydrogel film. In animal models, Carbylan- S containing
mitomycin C and Carbylan-SX were effective in prevention of post-operative intra-abdomi‐
nal adhesions [52,86].
17. Polylactide
Polylactide (copolymer of 70:30 poly(L-lactide-CO-D, L-lactide; SurgiWrap, MacroporeBio‐
surgeryinc., San Diego, USA) is a bioabsorbable film with a long absorption period (up to 6
months). It is metabolized to lactic acid and finally to CO2 and exhaled through the respira‐
tory system. It requires suturing in order to avoid its loss from the site. In preclinical studies,
polylactide appears to be effective in the reduction of adhesion formation, but there are no
data currently for safety and efficacy in humans [87,88].
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18. Polyethylene glycol
Polyethylene glycol (SprayGel; Confluent Surgical, Waltham, Massachusetts, USA). It is a syn‐
thetic hydrogel formed when two polyethylene glycol-based liquids are sprayed together with
an air assisted sprayer at the target tissue, where they cross-link and form a hydrogel barrier.
One liquid is clear and one is coloured with methylene blue in order that facilitate its application.
The gel remains intact for approximately 5–7 days and then gradually breaks down by hydroly‐
sis and is cleared through the kidneys [89]. Drawbacks of the product are the intricacy of prepa‐
ration and application, the time required to cover the target tissue and the high cost. In a
prospective randomized controlled phase-III trial, in 40 patients undergoing myomectomy, pol‐
ylactide resulted in a significant decrease in the mean tenacity score. The extent of adhesions was
increased in the control group but the difference was not significant. Also, the proportion of ad‐
hesion-free patients at second-look laparoscopy was increased in the treatment group but the
difference was not statistically significant [89]. It has been approved for use in laparoscopic and
open surgery in Europe, but by the FDA only for use in open surgery in USA [22,25].
19. Carboxymethylcellulose
Carboxymethylcellulose is a high-molecular-weight polysaccharide, derivative of cellulose.
The mechanism of its absorption is not well known. It has been used in combination with rtPA
and with HA. A composite gel of carboxymethylcellulose and polyethylene oxide (Oxiplex;
FzioMed, San Luis Obispo, CA, USA) is a viscoelastic gel, which acts as a barrier between tissues
that inhibits protein deposition and thrombus formation [74]. The gel is absorbed by 6 weeks,
but in cases where large amounts of gel were applied in multiple layers to the surgically treated
sites or in cases of stage-IV endometriosis, small collections of gelatinous material were noted in
areas of gel application or in areas deep in the cul-de-sac [90]. In two blind randomized control‐
led trials, where patients underwent adnexal surgery, carboxymethylcellulose and polyethy‐
lene oxide showed a significant improvement of AFS score in the treated group, but not in all
clinical situations. It did not appear to provide this benefit to patients with grade-IV endometrio‐
sis [74,91]. Another double-blind prospective randomized controlled trial has shown that the
mean AFS score for patients in the treatment group was unchanged, while in control patients an
increased AFS score was noted [91]. No statistical pooling was feasible for these three studies,
since the data were not analysed and presented per randomization unit (they were analysed per
adnexa and not per patient). It is easy to use in laparoscopic surgery and it has been approved in
Europe for use in abdominal and pelvic surgery [25].
20. Fibrin glue
Fibrin glue (Tissucol; Baxter International, Deerfield, IL, USA) is a biological product. Fibrin
glue is made by mixing human fibrinogen with bovine thrombin, calcium and factor XIII
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[92]. Obviously, the use of human blood products raises a theoretical risk for transmission of
infectious diseases. According to the pathogenesis of adhesions, application of fibrin glue at
the traumatized peritoneal surfaces should increase adhesion formation. Possibly, fibrin
glue application confines fibrin deposition and averts the development of attachments be‐
tween opposing tissue surfaces. In animal studies, the use of fibrin glue has been shown to
decrease adhesion formation and reformation but clinical data are limited. Fibrin glue has
not been approved by the FDA for use in USA [22,47]. So far, no relevant data from trials in
humans have been published.
21. Carboxymethylchitosan
N,O-carboxymethylchitosan (Adhes-X, Chitogenics, New Jersey, USA) is a purified deriva‐
tive of chitin obtained from the exoskeleton of shrimp and has similar structure to hyaluron‐
ic acid and carboxymethylcellulose [93]. The product comprises both a clear gel and a
solution. The gel is placed initially at the sites of surgical trauma where it is tamped with a
laparoscopic instrument and subsequently the solution is placed at the same places. Its effi‐
cacy and safety have been confirmed in some animal models. A prospective randomized
controlled study, performed on 34 patients undergoing laparoscopy for various gynaecolog‐
ical indications, demonstrated a decrease in the recurrence, extent and severity of adhesions
and a decrease of de-novo adhesion formation at second-look laparoscopy, but none of these
findings were statistically significant [94].
22. Fluid barriers
Fluids constitute an ideal barrier agent because their action is not limited to the site of applica‐
tion. Their function is provided by hydrofloration of intra-peritoneal structures in the liquid
that is infused into the peritoneal cavity at the end of the surgical procedure. Hydrofloration
provides a temporary separation between raw peritoneal surfaces allowing independent heal‐
ing without the formation of adhesions. Possibly, fluid circulation in the peritoneal cavity con‐
tributes to the prevention of adhesion formation by diluting fibrinous exudates released from
traumatized surfaces. Fluid barriers may prevent adhesion formation both at the traumatized
area and elsewhere in the pelvis. The instillation of fluids in the peritoneal cavity may be associ‐
ated with some undesirable side effects, such as leakage from the incision, labial oedema, feel‐
ing of fluid moving around, abdominal discomfort, abdominal distension and complications
such as pulmonary and peripheral oedema. Large volumes of intra-peritoneal fluids may de‐
crease the peritoneum ability to confront bacterial infections [3,17,76].
23. Crystalloid solutions
Crystalloid solutions (Ringer’s lactate, NaCl 0.9%) are rapidly absorbed by the peritoneal
cavity, at a rate of 30–50 ml/h. Consequently, 24 h after the surgery, minimal or no crystal‐
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loid solution would be left in the peritoneal cavity. The instillation of crystalloids does not
seem to result in decreased adhesion formation. They are commonly used but they are not
approved for use as anti-adhesive agents [25,69,95]. Crystalloids have also been used in vari‐
ous combinations with heparin, steroids, antihistamines and other pharmacological agents
in randomized controlled trials, but none of them has been found effective in decreasing
post-operative adhesion formation or improving pregnancy rates [96].
24. Dextran
Dextran (32% dextran 70; Hyskon; Pharmacia, Piscataway, New Jersey, USA) is a 1–6-linked
dextrose polymer. A summary [26] of the available data from relevant RCT [37,97-99] dem‐
onstrated a decreased proportion of patients with adhesions at second-look laparoscopy in
the group that received 32% dextran 70, as compared with the group that did not. However,
despite the fact that the patients with improvement and deterioration in the adhesion score
at second-look laparoscopy were increased and decreased, respectively, in the treatment
group, when compared with the control group, this difference was not statistically signifi‐
cant. In addition, its use was associated with significant side effects as pulmonary and pe‐
ripheral oedema caused by its osmotic properties, liver function abnormalities, pleural
effusion and, rarely, allergic reactions or anaphylactic shock and disseminated intra-vascu‐
lar coagulation. It has not been approved for use as an anti-adhesive agent [3,17,100,101].
25. Polyglycan esters
Polyglycanesters (Adcon-P; Gliatech, Cleveland, Ohio) is a viscous bioabsorbable solution.
Its prototypes Adcon-L and Adcon-T/N were found effective for adhesion prevention in spi‐
nal and neurosurgical procedures. Experimental studies have shown that application of Ad‐
con-P effectively reduces development of post-operative intra-abdominal adhesions. There
are no data for the safety and the efficacy of this product in humans [102].
26. Icodextrin
Icodextrin 4% (Adept; Shire Pharmaceuticals, Basingstoke, Hampshire, UK) is a 1–4-linked
glucose polymer. Icodextrin 4% is a clear isomolar solution and does not predispose to infec‐
tion. It is absorbed gradually via the lymphatic system into the systemic circulation, where it
is digested to oligosaccharides by amylase. Amylase is absent from the human peritoneal
cavity. Preclinical studies had shown significant reduction of post-operative adhesions and
confirmed the safety of icodextrin 4%. It was indicated that the agent was more effective in
adhesion reduction when used as both an irrigant and post-operative instillate [103]. In a
small double-blind prospective randomized multicentre study, icodextrin 4% resulted in the
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reduction of incidence, severity and extent of adhesions but these results were not statistical‐
ly significant [104]. However, recently, in the largest prospective randomized double-blind
multicentre study for an anti-adhesive agent, icodextrin 4% has been shown to result in a
significant reduction of incidence, severity and extent of adhesions and a significant im‐
provement of AFS score. Also the study showed that icodextrin 4% prevents the deteriora‐
tion of pre-existing adhesions, considering that patients with the higher number of adhesion
lysed at initial surgery had the greater reduction in adhesion incidence [95]. A stratified
analysis of these two studies revealed a statistically significant effect oficodextrin 4% use on
the de-novo formation of adhesions, as well as on the proportion of patients with an im‐
provement of the adhesion score at second-look laparoscopy [105]. Simultaneously with
clinical trials, a European patients registry (ARIEL) was created allowing surgeons to record
and report the experiences of the use of icodextrin 4% in open and laparoscopic gynaecolog‐
ical and general surgery. The registry provides feedback on routine use in 4620 patients
(2882 that underwent gynaecological and 1738 general surgery). The general consensus is
that it is easy to use in both open and laparoscopic surgery, it is well tolerated by patients
and the incidence of adverse events is considered similar to the control group [76,106]. Low
cost is another advantage of icodextrin 4%. Adept (1.5 litre bags) are about half the price of
each sheet of Interceed or Seprafilm and it is about four times cheaper than one SprayGel
package [50]. Icodextrin 4% has been approved for use in open and laparoscopic surgery in
Europe and it was the first anti-adhesive agent that has been approved by the FDA for use
in laparoscopic surgery in the USA [25,76,91,95].
27. Conclusions
Development of post-operative adhesion is a widespread consequence of surgical trauma
and healing following open or laparoscopic gynecological surgery and is associated with
significant complications. At present, the main strategy to avoid formation and reformation
of adhesions is focused on the use of careful surgical techniques and anti-adhesive agents.
Reduction of adhesion formation after laparoscopic surgery in comparison to the more con‐
ventional approach by laparotomy can be attributed to less tissue manipulation, less tissue
drying, avoidance of insertion of foreign bodies such as talc from the surgical gloves, fibers
from the gauzes e.t.c. On the other hand pneumoperitoneum during laparoscopy exerts a
tamponade effect that facilitates hemostasis, so minimizing the use of electrocautery, which
is known that leads to the formation of ischaemic areas and therefore predisposing to adhe‐
sion formation. The use of CO2 for pnemoperitoneum may lead to adhesion formation, since
its use is associated with reduction in tissue oxygenation, acidosis and release ofreactive
oxygen species, which are considered adhesiogenic. Therefore, the addition of oxygen, the
heating of the insufflatedCO2 or the alternative use of other gases (i.e. helium) may be bene‐
ficial in terms of reduction of de novo adhesion formation. At the end of each operation an
«underwater» examination should be used in order to document complete intra-peritoneal
hemostasis, since it has been clearly demonstrated that incomplete hemostasis is associated
with adhesion formation.
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Finally, several anti-adhesive agents are used during laparoscopic intrventions, in order to
minimizepostoperative adhesions. These fall into two main categories, which include phar‐
macological agents and barrier methods. Limited data support the use of the former, either
locally or systemically. Barriers, which mechanically separate the opposed serosal surfaces
and exert their beneficial action, at least partly, because they remain in place beyond the crit‐
ical 3-day point, at which competition of fibrinolytic activityandfibrosis will lead to adhe‐
sion formation. The tissue separation can be achieved either by the use of solid (films or gel)
or fluid barriers. The clinical effectiveness of several of these agents has been thoroughly
evaluated in two recent Cochrane reviews by Metwally et al [26] and Ahmad et al [51].
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